ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Debt-to-EBITDA : -7.93 (As of Sep. 2016)

ARIAD Pharmaceuticals Debt-to-EBITDA Chart

ARIAD Pharmaceuticals Annual Data
	Trend	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13	Dec14	Dec15
Debt-to-EBITDA		Get a 7-Day Free Trial					-0.11	-0.05	-0.40	-2.43	-2.18

ARIAD Pharmaceuticals Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16
Debt-to-EBITDA	Get a 7-Day Free Trial															-2.03	-2.26	-2.56	1.02	-7.93

Competitive Comparison of ARIAD Pharmaceuticals's Debt-to-EBITDA

For the Biotechnology subindustry, ARIAD Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARIAD Pharmaceuticals's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARIAD Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ARIAD Pharmaceuticals's Debt-to-EBITDA falls into.

ARIAD Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ARIAD Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

ARIAD Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2016) EBITDA data.

ARIAD Pharmaceuticals  (NAS:ARIA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

ARIAD Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description